Your trusted source

AstraZeneca has said it could take between six and nine months to produce Covid-19 vaccines that are effective against new variants of the coronavirus, and begin administering them to the public, The Guardian reports.

The company’s vaccine, developed jointly with scientists at the University of Oxford, remains effective against the original virus and at least one variant, first discovered in Kent, England. But preliminary findings in a small-scale trial prompted South Africa to limit its use while it ascertains its efficacy against the variant that emerged there.

A six-month turnaround for an updated vaccine would represent a vast improvement over traditional vaccine development timelines.

“Work on the variants hasn’t started today, it started weeks and months ago, as soon as those new variants were identified and … we are aiming to be in the clinic in the spring, with next generation vaccines for the new variants,” said Sir Mene Pangalos, executive vice-president, BioPharmaceuticals R&D at AstraZeneca.

Pangalos added that the jabs could be available to the public by the autumn, assuming the regulatory bodies are satisfied with using studies into the body’s immune response to the vaccine as the route to approval.

A number of Covid vaccines have shown lower efficacy in trials where the South Africa variant predominates: earlier this week preliminary trials revealed the Oxford/AstraZeneca jab provided little protection against mild to moderate infection, although it is still expected to protect against severe disease and death.